Alexander E. Drilon, MD, discusses the prevalence of <em>RET</em> fusions and mutations in patients with cancer, including lung and thyroid cancers.
Alexander E. Drilon, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the prevalence ofRETfusions and mutations in patients with cancer, including lung and thyroid cancers.
In lung cancer, or more specifically nonsmall cell lung cancer, where there are about 200,000 cases every year,RETmutations affect up to 2% of the population. In papillary thyroid cancer,RETmutations are found in 10% to 20% of patients.
In medullary thyroid cancer,RET
Anticipating Novel Options for the RAI-Refractory DTC Armamentarium
May 15th 2023In season 4, episode 6 of Targeted Talks, Warren Swegal, MD, takes a multidisciplinary look at the RAI-refractory differentiated thyroid cancer treatment landscape, including the research behind 2 promising systemic therapy options.
Listen
Behind the FDA Approval of Liso-cel for Relapsed/Refractory CLL/SLL
March 15th 2024In an interview with Targeted Oncology, Tanya Siddiqi, MD, discussed the rationale behind the TRANSCEND CLL 004 study supporting the FDA approval of lisocabtagene maraleucel in chronic lymphocytic leukemia or small lymphocytic lymphoma.
Read More